November 20, 2020Download pdf
Bresso (Milano); Italy - 20 November, 2020 - EryDel SpA, a global late-stage biotech company aimed at developing and commercializing therapies for the treatment of rare diseases delivered by its proprietary red blood cell technology, announced today the appointment of Carlo Incerti as Chairman of its Board of Directors.
“The addition of Carlo as Chairman of the Board comes at a critical time of the development of our key program in Ataxia Telangiectasia, with top line data readout in 1q 2021, said Luca Benatti (CEO) "we are very pleased to welcome Carlo and look forward to counting on his expert engagement, talent and energy to further our mission".
Carlo brings over three decades of experience in the biopharmaceutical industry both in drug development/licensing and in product launches. He held several positions of increasing scope and responsibility at Genzyme Corporation where he was later appointed as Chief Medical Officer and Head of Global Medical Affairs. Carlo is an Operating Partner at Forbion Capital Partners, Chairman of the Board at Inversago Pharma and Azafaros B.V. Most recently Carlo was Chairman of the Board of Molmed SpA, a public Italian company active in cell and gene therapy, which was sold in July to the Japanese company AGC. Carlo for many years has been a member of the Board of EuropaBio, serving as its Chairman for four years and is a founding member of the International Rare Diseases Research Consortium. Prior to joining the industry, Carlo was an Associate Professor of Endocrinology at the University of Modena.
Carlo said: "I am excited to join Erydel at a time when the read-out of top line data of the ATTeST study, the Phase 3 pivotal trial in Ataxia Telangiectasia (AT), is near. I have been working for most of my professional life to discover and develop drugs for rare disorders and EryDex represents an ideal continuation of this journey, with its potential to meaningfully impact the life of patients suffering from AT and of their families. I am looking forward to supporting Luca and his Team in this endeavor with my passion and experience."
EryDel SpA, a global, late-stage biotech company aimed at developing and commercializing therapies for the treatment of rare diseases delivered by its proprietary red blood cell (RBC) technology. Its most advanced product, EryDex is under late stage development for the treatment of Ataxia Telangiectasia, a rare autosomal recessive disorder for which no established therapy is currently available. A completed Phase II trial in AT patients demonstrated statistically significant efficacy of EryDex on both the primary and secondary efficacy measures. An international multi-center, Phase III pivotal study, ATTeST, is currently being conducted. EryDel has a pipeline of preclinical programs that use its proprietary RBC delivery technology for the treatment of other rare diseases including enzyme replacement therapies.
For further information, please contact: Emanuela Germi at +39 02 36504470 or firstname.lastname@example.org